Trikafta Shows Sustained Anti-Inflammatory Effects in Cystic Fibrosis Patients Through 2.5 Years
核心洞察
New research demonstrates that Trikafta (elexacaftor/tezacaftor/ivacaftor) produces sustained reductions in key inflammatory markers in cystic fibrosis patients that persist through 2.5 years of treatment.
The PROMISE study found significant decreases in neutrophil elastase (搜索) activity, calprotectin (搜索), IL-1β (搜索), and IL-8 (搜索) within the first month of therapy that remained stable at 24-30 months.
Advanced 129Xenon MRI imaging shows greater sensitivity than traditional lung function tests in detecting treatment responses, particularly in pediatric patients with preserved lung function.
Adults and adolescents with cystic fibrosis receiving Trikafta (elexacaftor/tezacaftor/ivacaftor) therapy demonstrate sustained reductions in airway and systemic inflammation that persist through 2.5 years of treatment, according to new data from the PROMISE study published in Annals of the American Thoracic Society. The findings provide crucial insights into the long-term anti-inflammatory effects of the triple combination therapy beyond its established benefits for lung function.
Sustained Inflammatory Marker Reductions
The PROMISE substudy evaluated 223 patients (mean age 24.5 years, 53% female) with cystic fibrosis receiving ETI therapy for the first time. Researchers found significant decreases in four key inflammatory markers within the first month of treatment that remained stable at the 24-30 month timepoint: sputum neutrophil elastase (搜索) activity, calprotectin (搜索), interleukin-1β, and IL-8 (搜索).
"We were pleased to see that ETI was associated with sustained reductions in several serum and sputum inflammatory measurements through 2.5 years of ETI therapy," said Scott D. Sagel, MD, PhD, professor of pediatrics-pulmonary medicine at the University of Colorado School of Medicine (搜索).
Circulating high-sensitivity C-reactive protein (hsCRP) also showed significant reductions in the first month, continuing through 12-18 months, the last assessed timepoint for this serum marker. These inflammatory improvements occurred alongside significant clinical improvements in percent-predicted FEV1, BMI, CF Questionnaire-Revised respiratory domain scores, and sweat chloride levels.
Disease Severity Influences Treatment Response
The study revealed that patients with more severe disease experienced greater anti-inflammatory benefits. Those with ppFEV1 less than 80% showed significantly larger reductions in serum hsCRP, sputum neutrophil elastase (搜索) activity, sputum calprotectin (搜索), sputum IL-1β (搜索), interferon gamma, and tumor necrosis factor-alpha compared to patients with ppFEV1 of 80% or higher.
Similarly, patients infected with P. aeruginosa demonstrated significantly larger decreases in sputum neutrophil elastase (搜索) activity and interferon gamma versus uninfected patients. Despite these improvements, Sagel noted that "there is still evidence of ongoing airway inflammation based on the presence of free neutrophil elastase activity in several study participants, more so in adults, those with lower ppFEV1 and those infected with P. aeruginosa."
Advanced Imaging Reveals Enhanced Sensitivity
Complementary research from the HyPOINT study demonstrates that 129Xenon MRI provides superior sensitivity for detecting treatment responses compared to traditional lung function measures. The study of 25 pediatric patients (mean age 13 years) found that Xe MRI outcomes showed greater relative improvements than lung clearance index and FEV1.
Felix A. Ratjen, MD, PhD, from The Hospital for Sick Children, and colleagues reported mean relative changes of 71.8% for reader-defect percentage (RDP) and 42.7% for ventilation defect percentage (VDP), compared to 11.1% for lung clearance index and 8% for FEV1. These improvements remained stable at 12 months in the 21 patients with available data.
Clinical Trial Implications
The enhanced sensitivity of Xe MRI has significant implications for future clinical trials. The researchers calculated that detecting treatment effects would require only 12 participants for RDP and 28 for VDP, compared to 68 participants for lung clearance index and 114 for FEV1.
"These findings highlight the potential for Xe MRI as a sensitive tool for future multi-center, interventional studies, especially in people with CF with preserved pulmonary function," Ratjen and colleagues wrote.
Notably, the imaging technique detected improvements in patients with normal-range lung function where traditional measures showed minimal changes. Among 14 patients with FEV1 >90% predicted, relative improvements in RDP reached 88.9% and VDP 54.3%, while lung clearance index improved only 9.3% and FEV1 by 5.4%.
Ongoing Research Directions
The PROMISE study continues to monitor patients through 4.5 years of ETI therapy to assess the durability of inflammatory changes. Researchers are also examining relationships between airway infection and inflammation changes over time, and investigating whether patients with persistent inflammation experience more rapid lung function decline.
"Somewhat surprisingly, we are seeing lung function decline, albeit at a modest rate, in these study participants," Sagel noted. "It may be attributed in part to suboptimal adherence to ETI therapy and to discontinuation of other chronic respiratory therapies. Persistent inflammation may be another explanation."
The findings support the potential need for adjunctive anti-inflammatory therapies in certain patient populations, particularly those with evidence of ongoing neutrophilic inflammation despite CFTR (搜索) modulator therapy.